IL3RA and acute myeloid leukemia: Similar to monoclonal-based therapies, CD33 and CD123 are ideal targets for CAR-T cell therapy because they are mostly AML cell- and LSC-specific antigens, though their expression on normal cells has limited therapy more than anti-CD19.